Erschienen in:
23.03.2016 | Translational Research and Biomarkers
Clinicopathologic Characteristics of Patients with HER2 Insertions in Non-small Cell Lung Cancer
verfasst von:
Shi Bu, Rui Wang, Yunjian Pan, Su Yu, Xuxia Shen, Yuan Li, Yihua Sun, Haiquan Chen
Erschienen in:
Annals of Surgical Oncology
|
Ausgabe 1/2017
Einloggen, um Zugang zu erhalten
Abstract
Background
The human epidermal growth factor receptor-2 (HER2) genes have been described in a subset of non-small cell lung cancer (NSCLC). To help identify and treat these patients, we investigated the frequency, clinicopathologic characteristics, and clinical outcomes of patients who had NSCLC with or without HER2 insertions.
Methods
The mutational status of the HER2 (exons 19–20) gene was assessed in a cohort of 1875 patients with NSCLC. All patients were also analyzed for mutations in EGFR, KRAS, BRAF, ALK, RET, and ROS1. Clinical characteristics, including age, sex, smoking status, stage, histology, tumor size, differentiation, overall survival, and relapse-free survival, were collected.
Results
Among 1875 NSCLCs examined, 35 (1.9 %) were HER2 insertion. Compared with the HER2 insertion-negative group, patients with HER2 insertions were more likely to be never smokers (97.1 %, 34/35 patients, P < 0.001), significantly associated with female (91.4 %, 32/35 patients, P < 0.001), adenocarcinoma (91.4 %, 32/35 patients, P = 0.01), and with a tendency to be no more than 60 years of age (71.4 %, 25/35 patients, P = 0.051).
Conclusions
HER2 insertion could define a distinct subset of NSCLC, which had a higher prevalence among females, nonsmokers, and adenocarcinoma. HER2 should be in the clinical genotyping of lung cancer, so patients may benefit from HER2-targeted therapy.